EQ 200 / Test E 200
EQ 200 / Test E 200 Dragon Pharma — Overview
EQ 200 / Test E 200 Dragon Pharma is a pre-mixed injectable blend combining boldenone undecylenate at 200 mg/mL and testosterone enanthate at 200 mg/mL in a single vial — 400 mg/mL total. Drawing from one vial instead of two delivers the testosterone base and the boldenone component in a single injection without the need to measure and combine separate products. The blend is optimized for lean mass cycles where the appetite-stimulating, red blood cell-elevating, and moderate-aromatization properties of boldenone complement the anabolic and androgenic foundation of testosterone enanthate.
This page covers the pharmacology of each component, how they interact in the blend, cycle structure, Dragon Pharma add-on options, side effect management, and PCT. One important timing note specific to this product: because boldenone undecylenate has a longer ester half-life than testosterone enanthate, PCT should begin 21 days after the last injection — not 14.
About the Blend: Boldenone Undecylenate + Testosterone Enanthate
The two compounds in this blend share a long-ester format but have meaningfully different pharmacological profiles that make them complementary rather than redundant.
Testosterone enanthate (200 mg/mL): the C8 ester of testosterone with a plasma half-life of approximately 4.5 days and an active life of 8–10 days. Testosterone is the primary androgen receptor agonist in the stack — it drives the majority of the direct anabolic and androgenic signaling, sets the hormonal baseline, and provides the libido and wellbeing effect that boldenone alone cannot. Aromatization is high at a per-milligram level, so the testosterone component is responsible for most of the estradiol conversion in the blend.
Boldenone undecylenate (200 mg/mL): a testosterone derivative with an 11-carbon ester that gives it a half-life of approximately 14 days — nearly three times longer than the enanthate ester. Boldenone aromatizes at approximately 50% the rate of testosterone per milligram, which means that despite the equal per-mL concentrations, the boldenone component contributes significantly less to overall estradiol production than the testosterone component. Boldenone's distinguishing characteristics are: substantial appetite stimulation (one of the most consistent and pronounced effects in AAS use, which makes it particularly valuable in caloric surplus phases), lean and relatively dry tissue accrual, improved vascularity as body fat decreases, and strong erythropoiesis stimulation — boldenone increases red blood cell production and hematocrit more reliably and to a greater degree than testosterone at equivalent doses.
Together in equal 200 mg/mL concentrations, the blend produces an overall aromatization rate that is lower than the same weekly dose of pure testosterone, lean-quality tissue gains with reduced water retention relative to testosterone-only protocols, and the boldenone appetite and vascularity benefits on top of the testosterone androgenic foundation.
What EQ 200 / Test E 200 Does
The effects of this blend are the combined output of both components. Effects unique to or amplified by the boldenone component are noted:
- Lean mass accrual with reduced water retention — the testosterone component drives androgen receptor-mediated protein synthesis and nitrogen retention; the boldenone component adds to this signal with lower estrogenic conversion, resulting in a drier, harder look compared to testosterone-only cycles at the same weekly mg dose; at 400–600 mg/week of the blend (200–300 mg of each compound), quality lean tissue accumulates without the pronounced glycogen-driven water retention typical of testosterone-only or testosterone plus Dianabol cycles.
- Appetite stimulation — boldenone undecylenate produces a reliable and often significant increase in appetite beginning in weeks 3–5 as blood levels stabilize; this is one of the most practically useful effects in the blend for users trying to maintain a caloric surplus during an extended mass cycle; the appetite effect is the boldenone component's signature and distinguishes this blend from combinations that use primobolan or masteron as the second compound.
- Vascularity and muscular fullness — boldenone improves visible vascularity as a consequence of increased red blood cell count, elevated muscle glycogen density, and reduced subcutaneous water; this effect becomes more pronounced in the second half of the cycle and is more visible as body fat decreases; the visual result is a fuller, harder, more vascular appearance that distinguishes EQ-based cycles from testosterone-only bulking cycles.
- Red blood cell elevation and oxygen-carrying capacity — boldenone is among the most potent erythropoiesis-stimulating AAS compounds; it raises hematocrit, hemoglobin, and red blood cell count significantly and consistently; increased RBC count improves exercise capacity, muscle endurance, and recovery between sessions; this is a meaningful performance effect but must be monitored — see Side Effects for the hematocrit management protocol.
- Strength gains — the testosterone component provides the primary strength output through direct androgen receptor activation in skeletal muscle and motor neurons; boldenone adds to this indirectly via the RBC and nitrogen-retention contribution; strength increases begin in weeks 3–5 and accumulate through the cycle duration, though they are less dramatic in peak rate than Dianabol- or trenbolone-based cycles.
- Moderate estrogenic environment — the overall E2 production from this blend is lower than an equivalent weekly dose of pure testosterone, which makes estrogen management more straightforward; many users run this blend with a lower AI dose or a more conservative AI protocol than they would use on a testosterone-only cycle at the same weekly mg total; the practical result is less water retention, less gynecomastia risk, and less need for aggressive AI titration.
Who It Is For
EQ 200 / Test E 200 is well-suited to intermediate and advanced users who want the lean-mass, vascularity, and appetite-stimulation profile of an EQ-based cycle without the inconvenience of drawing from two separate vials and measuring individual volumes. It is not a beginner compound:
- Intermediate users who have completed at least one testosterone cycle and are ready to add the boldenone component for cleaner, longer-duration mass gains — boldenone's long ester makes short cycles inefficient; a minimum of 12 weeks, ideally 14–16, is needed for the compound to produce its full effect
- Athletes in body composition phases who want to maximize lean tissue accumulation with controlled water retention and moderate estrogen management requirements — the reduced aromatization relative to testosterone-only makes this blend more compatible with leaner, drier training phases than a pure-testosterone approach
- Users who struggle with appetite during caloric surplus phases — the boldenone-driven appetite stimulation is a practical tool for athletes who find it difficult to eat enough on extended bulk cycles; this is a frequently cited reason for choosing EQ-based cycles over primobolan or masteron combinations, both of which lack this appetite effect
- Athletes who want the performance and recovery benefit of elevated red blood cell count — the hematocrit increase from boldenone is meaningful for endurance athletes and those doing high-volume training, but requires bloodwork monitoring; users with a history of elevated hematocrit, polycythemia, or cardiovascular risk factors should exercise more caution and monitor more frequently
- Advanced users looking for a clean base compound in a multi-drug protocol who want to reduce injection volume and complexity — the pre-mixed format simplifies protocol administration compared to dosing boldenone and testosterone separately
Recommended Combinations
EQ 200 / Test E 200 already contains the testosterone base and boldenone component. Combinations below add a third compound for specific goals. Dragon Pharma products throughout:
| Goal | Stack | Notes |
|---|---|---|
| Lean mass base (blend only) | EQ 200 / Test E 200 at 600 mg/week | 600 mg/week of the blend = 300 mg boldenone + 300 mg testosterone per week; at this dose, 1.5 mL per week (split E3.5D into two injections of 0.75 mL each); the blend alone is sufficient for a productive lean mass cycle for most intermediate users; AI at low to moderate dose from day 1 based on bloodwork; 14–16 week cycle preferred to allow the slow boldenone undecylenate ester to reach steady state and produce its full effect by weeks 6–8 |
| Lean mass with oral finisher | EQ 200 / Test E 200 + Anavar 50 Dragon Pharma | Anavar added in the final 8–10 weeks of the cycle (weeks 6–14 or 8–16) when the boldenone component has fully built up; Anavar contributes hardness, strength, and lean tissue protection without additional estrogenic load; EQ 200/Test E 200 at 400–600 mg/week; Anavar 50 at 25–50 mg/day; the combination produces a lean, vascular result with relatively manageable side effects; AI at low dose given the already-moderate aromatization from the blend; a consistently favored combination for athletes prioritizing body quality over maximum scale weight |
| Mass with oral kickstart | EQ 200 / Test E 200 + Dianabol 20 Dragon Pharma | The boldenone component requires 5–7 weeks to reach full steady-state blood levels; Dianabol bridges this gap in weeks 1–4 or 1–6, providing rapid strength and mass gains while the long-ester compounds build up; Dianabol 20 at 40–60 mg/day for weeks 1–4 or 1–6; EQ 200/Test E 200 at 600 mg/week for 14–16 weeks; full liver support (Liv.52, NAC) while Dianabol is active; AI from week 1 given Dianabol's strong aromatization contribution; appetite effect from boldenone sustains the caloric surplus once Dianabol is discontinued |
| Pre-contest lean and dry | EQ 200 / Test E 200 + Winstrol 50 Dragon Pharma | EQ's vascularity and Winstrol's hardening effect are synergistic in the final contest prep phase; Winstrol 50 at 25–50 mg/day for the final 6–8 weeks of the cycle; EQ 200/Test E 200 at 400 mg/week; Winstrol binds SHBG, freeing more testosterone and boldenone for androgen receptor interaction; the combination produces a hard, dry, vascular appearance; liver support while Winstrol (oral) is running; Winstrol Inject Dragon Pharma is available as an alternative for those preferring the injectable format |
| Advanced mass | EQ 200 / Test E 200 + Trenbolone 200 Dragon Pharma | For experienced athletes; trenbolone's exceptional anabolic potency and nutrient partitioning combined with boldenone's RBC stimulation and appetite effect creates a high-output mass stack; EQ 200/Test E 200 at 400–600 mg/week; Trenbolone 200 at 200–400 mg/week; the trenbolone component brings significant cardiovascular, sleep, and prolactin management requirements; cabergoline for prolactin; blood pressure monitoring; AI for the testosterone component's E2; hematocrit monitoring is more critical here given both boldenone and trenbolone's erythropoietic effects |
Side Effects & Management
The side effect profile reflects both components of the blend. Several effects — particularly hematocrit elevation and appetite increase — are meaningfully more pronounced with the boldenone component than with testosterone alone and receive detailed treatment below.
| What May Occur | Background | How to Handle It |
|---|---|---|
| Hematocrit and hemoglobin elevation — the primary safety concern with EQ | Boldenone undecylenate is a potent erythropoiesis stimulator — more so than testosterone at equivalent doses; it increases EPO production and acts on bone marrow precursor cells to raise RBC count, hemoglobin, and hematocrit substantially; hematocrit above 52–54% significantly increases blood viscosity, which elevates the risk of thrombotic events (DVT, pulmonary embolism, stroke); on EQ-based cycles at 400–600 mg/week, hematocrit commonly reaches 52–56% without management; the effect compounds if the testosterone component also drives erythropoiesis; this is the most clinically significant unique risk of boldenone-containing cycles and must be actively monitored throughout | Baseline CBC before cycle start; repeat CBC and full blood panel every 6 weeks while on cycle — more frequently than testosterone-only cycles; if hematocrit exceeds 52%: reduce dose of the blend (the boldenone component is the primary driver); increase hydration significantly — dehydration concentrates blood viscosity; if hematocrit exceeds 54% and does not respond to dose reduction and hydration: therapeutic phlebotomy (blood donation or clinical phlebotomy) is the most direct intervention; Ecosprin (Aspirin) 81 mg daily from week 1 onward for antiplatelet support throughout the cycle duration; do not run this blend if baseline hematocrit is already above 48% |
| Appetite stimulation (pronounced) | Boldenone reliably and significantly increases appetite, typically becoming noticeable from weeks 3–5 as blood levels stabilize; the mechanism is not fully characterized but is consistent across users and dose levels; for athletes in a caloric surplus trying to maintain the intake required for a 14–16 week mass cycle, this effect is generally beneficial; for users on a caloric deficit or trying to manage body composition, the appetite drive can make adherence to caloric targets substantially harder | In a mass phase this requires no intervention — the appetite effect supports the dietary requirements of the cycle; in a cutting phase or for body composition-focused cycles where caloric intake is controlled, structuring meals (pre-portioned, timed) rather than eating to hunger is the practical approach; users who find the appetite effect disruptive to dietary management sometimes prefer primobolan or masteron as the second compound instead of boldenone — those compounds do not produce this effect |
| Estrogen-related: water retention, gynecomastia risk (lower than testosterone-only) | The testosterone component aromatizes at a high per-milligram rate; the boldenone component aromatizes at approximately 50% of testosterone's rate; at equal 200 mg/mL concentrations, the blend's overall E2 conversion is moderate — meaningfully lower than the same weekly mg dose as pure testosterone; water retention and gynecomastia risk are present but more manageable than in testosterone-only cycles; the reduced E2 load is one of the practical advantages of this blend format | AI from day 1 at a lower starting dose than a testosterone-only cycle — Arimidex Dragon Pharma 0.25–0.5 mg every other day or Aromasin Dragon Pharma 12.5 mg EOD; titrate based on bloodwork (target E2 on-cycle 20–40 pg/mL); aggressive AI use in a blend with only moderate aromatization can easily crash E2, causing joint pain, fatigue, and libido loss — err toward conservative initial dosing; for breakthrough gynecomastia symptoms, Nolvadex Dragon Pharma 20–40 mg/day |
| Androgenic: acne, oily skin, hair loss | Boldenone has a lower affinity for 5-alpha reductase than testosterone, meaning it converts to a less potent androgen (dihydroboldenone) rather than the more potent DHT that testosterone produces; the androgenic side effect burden from the blend is therefore lower than a pure testosterone cycle at the same weekly dose; however, the testosterone component still converts to DHT, and androgenic sides — acne, oily skin, accelerated hair loss in genetically susceptible users — remain present | For acne: topical benzoyl peroxide or salicylic acid for mild cases; Doxycycline 100 mg/day for moderate persistent acne; Isotroin (Isotretinoin) 20 mg/day for severe or cystic acne (liver panel required). For hair loss: Finasteride Dragon Pharma 1 mg/day reduces DHT from the testosterone component; note that finasteride does not reduce DHB (dihydroboldenone) — it only addresses the testosterone-derived DHT |
| Cardiovascular: blood pressure, lipid profile | Both testosterone and boldenone negatively impact the lipid profile (LDL up, HDL down) and contribute to blood pressure elevation; at the longer cycle lengths typical of EQ use (14–16 weeks), cumulative cardiovascular stress is greater than on shorter testosterone-only cycles; blood pressure elevation is amplified if hematocrit rises significantly, as thicker blood requires greater cardiac output; the 14–16 week timeframe of a typical EQ cycle requires sustained BP and lipid monitoring throughout | Lipid panel at baseline and every 6–8 weeks; for LDL management: Rosulip (Rosuvastatin) or Atorvastatin 40 mg Dragon Pharma; for BP above 130/85: Amlip (Amlodipine) 5 mg/day or Sartel (Telmisartan) 40–80 mg/day; Ecosprin (Aspirin) 81 mg/day throughout the cycle; managing hematocrit (see above) is the most effective single intervention for elevated BP in EQ cycles |
| HPTA suppression and testicular atrophy | Both testosterone and boldenone suppress LH and FSH via negative HPG feedback; suppression is complete; boldenone's long undecylenate ester means suppressive blood levels persist for longer after the last injection than with enanthate esters, which is why PCT is delayed to 21 days — starting PCT earlier while boldenone levels are still suppressive wastes SERMs and extends the suppression window unnecessarily | On-cycle: HCG 5000 IU Dragon Pharma at 250–500 IU twice weekly from week 4 onward; discontinue at least 4 days before PCT SERMs; start SERMs 21 days after the last blend injection (not 14 — boldenone's longer ester determines this wait time) |
PCT — Post-Cycle Therapy
The PCT wait of 21 days (not 14) is the critical difference between this blend and enanthate-only protocols. Boldenone undecylenate clears significantly more slowly than testosterone enanthate; starting SERMs at day 14 when boldenone levels are still meaningfully suppressive will not produce adequate HPG axis recovery. Wait the full 21 days.
| Phase | Products | Protocol |
|---|---|---|
| Pre-PCT: HCG blast (recommended) | HCG 5000 IU Dragon Pharma or HCG 2500 IU Dragon Pharma | If HCG was not used on-cycle: 2,500 IU on days 1, 3, and 5 of the 21-day clearance window; primes testicular testosterone production before SERM therapy begins; more important after 14–16 week cycles where testicular volume loss is more pronounced; discontinue at least 4 days before the first SERM dose |
| PCT weeks 1–2 | Clomid Dragon Pharma + Nolvadex Dragon Pharma | Clomid 50 mg/day + Nolvadex 40 mg/day; start 21 days after the last EQ 200 / Test E 200 injection; Clomid drives LH and FSH at the pituitary level; Nolvadex restores GnRH pulsatility at the hypothalamus by blocking estrogen negative feedback |
| PCT weeks 3–4 | Clomid Dragon Pharma + Nolvadex Dragon Pharma | Clomid 25 mg/day + Nolvadex 20 mg/day; taper phase allows natural LH/FSH feedback to reassert; bloodwork at 4 weeks into PCT confirms testosterone and LH/FSH recovery trajectory; after a 16-week cycle, extending PCT to 6 weeks (maintaining weeks 3–4 dosing through week 6) is worth considering if bloodwork at week 4 shows incomplete recovery |
| Alternative SERM options | Enclomiphene Dragon Pharma or Toremifene Dragon Pharma | Enclomiphene 25 mg/day for 4–6 weeks as a standalone SERM; Toremifene 60 mg/day as a Nolvadex substitute; these are alternatives to the Clomid/Nolvadex pair, not additions; start at day 21 post-last-injection in either case |
References
| Source | Topic | Link |
|---|---|---|
| PubMed / New England Journal of Medicine | Supraphysiologic testosterone enanthate in normal men — randomized controlled trial using 600 mg/week testosterone enanthate for 10 weeks, showing increased fat-free mass, muscle size, and strength, especially when combined with resistance training | Bhasin et al., 1996 ↗ |
| NCBI Bookshelf / StatPearls | Anabolic steroids overview — synthetic testosterone-derived AAS pharmacology, androgen receptor mechanism, anabolic-androgenic effects, injectable ester context, misuse patterns, monitoring, and adverse effect profile | StatPearls: Anabolic Steroids ↗ |
| NCBI Bookshelf / Endotext | Androgen physiology and pharmacology — testosterone and androgen derivative mechanisms of action, androgen receptor activity, HPG axis suppression, estradiol aromatization, androgen ester pharmacokinetics, and androgen misuse context | Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗ |
What is EQ 200 / Test E 200?
EQ 200 / Test E 200 is an injectable steroid blend of Testosterone Enanthate and Boldenone Undecylenate; see What is Testosterone Enanthate, Boldenone Undecylenate. It promotes lean muscle—consult professionals for safe use.
What is EQ 200 / Test E 200 used for?
It's used for lean muscle growth and strength in bodybuilding; see Key Benefits. It suits bulking or cutting—consult professionals for safe use.
How long does EQ 200 / Test E 200 stay in your system?
With half-lives of 7-14 days, it's detectable for 3-6 months; see Mechanism of Action. Plan PCT accordingly—consult professionals.
Is EQ 200 / Test E 200 dangerous?
It's safe with proper use and monitoring; see Side Effects. Risks are manageable with ancillaries—consult professionals for safety.
How to use EQ 200 / Test E 200?
Inject 400-800 mg/week, split weekly; see How to Use. Use with diet and monitoring—consult for tailored plans.
How does EQ 200 / Test E 200 work?
The blend combines the anabolic effects of boldenone undecylenate with the muscle-building properties of testosterone enanthate, providing sustained activity through their long ester profiles.
How long does it take to notice the effects of EQ 200 / Test E 200?
Because both compounds are long-acting esters, results tend to develop gradually. Many users report improvements in training performance, recovery, muscle fullness, and endurance over several weeks.
What are the main benefits of EQ 200 / Test E 200?
Commonly reported benefits include lean muscle development, increased strength, improved recovery, enhanced workout performance, and support for long-term physique improvement.
Related Products
